Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer
10.3971/j.issn.1000-8578.2022.22.0453
- VernacularTitle:MSS型结直肠癌免疫联合治疗研究进展
- Author:
Zhucheng YIN
1
;
Xinjun LIANG
Author Information
1. Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430079, China
- Publication Type:Research Article
- Keywords:
Colorectal cancer;
pMMR;
MSS;
Immunotherapy
- From:
Cancer Research on Prevention and Treatment
2022;49(9):977-981
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy has achieved great progress in the treatment of malignant tumors and has enriched the treatment mode of many types of malignant tumors. Colorectal cancer is a common tumor worldwide. Immune checkpoint inhibitor therapy for patients with metastatic colorectal cancer (mCRC) featuring DNA mismatch repair deficiency/high microsatellite instability has significant clinical benefits, but approximately 95% of patients with mCRC are DNA mismatch repair proficient/microsatellite stable (MSS). These patients have poor response to immunotherapy. Therefore, strategies to improve the efficacy of immunotherapy in patients with this type of tumor have attracted considerable attention. This article reviews the research progress on combined immunotherapy for MSS mCRC.
